Bristol Myers Squibb Stock Earns 83 RS Rating

Blockhead
20 Dec 2024

On Thursday, Bristol Myers Squibb (BMY) stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.

X
This Is How A New President Will Impact Fed Rate Cuts In 2025
See All Videos
NOW PLAYING This Is How A New President Will Impact Fed Rate Cuts In 2025

IBD's proprietary rating tracks price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.

Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves.


Looking For The Best Stocks To Buy And Watch? Start Here


Is Bristol Myers Squibb A Buy?

Bristol Myers Squibb stock is building a with a 61.08 entry. See if it can break out in heavy trading. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.

The drug maker posted -10% earnings growth in its most recent report. Sales rose 8%.

Bristol Myers Squibb stock earns the No. 3 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health (PAHC) is the top-ranked stock within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."

YOU MAY ALSO LIKE:

Learn How To Time The Market With IBD's ETF Market Strategy

Find Today's Best Growth Stocks To Watch With IBD 50

Find The Best Long-Term Investments With IBD Long-Term Leaders

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10